Delvys Rodríguez‐Abreu

Author

Hospital Universitario Insular de Gran Canaria ORCID

Also Known As

Constanza Maximiano, D Rodriguez Abreu, D. Rodriguez Abreu, D. Rodriguez-Abreu, D. Rodriguez-abreu, D. Rodríguez - Abreu, D. Rodríguez Abreu, D. Rodríguez-Abreu, Delvys Abreu, Delvys Rodriguez Abreu

379

Publications

46.6K

Citations

H-Index

Concepts

All Affiliations

Hospital Universitario Insular de Gran Canaria Universidad de Las Palmas de Gran Canaria Merck & Co., Inc., Rahway, NJ, USA (United States)Hospital Universitario Fundación Jiménez Díaz Institut Català d'Oncologia

About

Delvys Rodríguez‐Abreu is an author at Hospital Universitario Insular de Gran Canaria specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	36	66	10.3K
2	Health Sciences	17	20	1.6K
3	Allergy	2	2	257
4	Biostatistics	1	1	24
5	Diagnostic Sciences	1	1	15

Delvys Rodríguez‐Abreu

127

Publications

40.8K

Citations

H-Index

Page 1

	Year	Citations
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer Martin Reck, Delvys Rodríguez‐Abreu, Andrew Robinson, New England Journal of Medicine	2016	9.8K
Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer Leena Gandhi, Delvys Rodríguez‐Abreu, Shirish M. Gadgeel, New England Journal of Medicine	2018	6.4K
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial Rafael Rosell, Enric Carcereny, Radj Gervais, The Lancet Oncology OncologyStandard ChemotherapyRandomised Phase 3PathologyBronchial Neoplasm	2012	5.5K
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC Mark A. Socinski, Robert M. Jotte, Federico Cappuzzo, New England Journal of Medicine	2018	3.7K
Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater Martin Reck, Delvys Rodríguez‐Abreu, Andrew Robinson, Journal of Clinical Oncology	2019	1.6K
Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non–Small-Cell Lung Cancer Shirish M. Gadgeel, Delvys Rodríguez‐Abreu, Giovanna Speranza, Journal of Clinical Oncology	2020	1.1K
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50% Martin Reck, Delvys Rodríguez‐Abreu, Andrew Robinson, Journal of Clinical Oncology	2021	1K
Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer Heather A. Wakelee, Moïshe Liberman, Terufumi Kato, New England Journal of Medicine	2023	903
Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial Mariano Provencio, Ernest Nadal, Amelia Insa, The Lancet Oncology MedicineImmune Checkpoint InhibitorCancer TreatmentOncologyRadiation Oncology	2020	788
Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study Charles M. Rudin, Mark M. Awad, Alejandro Navarro, Journal of Clinical Oncology	2020	729

Page 1